Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Praliciguat · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Praliciguat | EXPERIMENTAL | Praliciguat will be administered daily with dose escalation to a target dose during a 24-week double-blind period, followed by a 24-week open-label treatment period. |
| Placebo | PLACEBO_COMPARATOR | Matching placebo will be administered daily for 24 weeks |
| Name | Type | Description |
|---|---|---|
| Praliciguat | DRUG | Oral Tablet |
| Placebo | OTHER | Oral Tablet |
Inclusion Criteria: 1. UPCR ≥1 (g/g) during screening. 2. On maximally tolerated ACEi or ARB per principal investigator discretion within 1 month of informed consent. 3. Estimated glomerular filtration rate ≥25 milliliters per minute per 1.73 square meters by Chronic Kidney Disease Epidemiology Col...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE2 | frexalimab, brivekimig, rilzabrutinib |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | Atrasentan |
| Akebia Therapeutics, Inc. | AKBA | 1 | PHASE2 | Praliciguat |
| Travere Therapeutics, Inc. | TVTX | 1 | PHASE2 | Sparsentan |
| Vera Therapeutics, Inc. Class A | VERA | 1 | PHASE2 | Atacicept |
Praliciguat is an investigational small molecule being developed for the treatment of Focal Segmental Glomerulosclerosis (FSGS), a kidney disorder. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Praliciguat is being developed by Akebia Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AKBA. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with FSGS.
Praliciguat is currently in Phase 2 clinical development. It is an investigational drug and has not yet received regulatory approval. The ongoing Phase 2 study is actively recruiting participants with Focal Segmental Glomerulosclerosis.
Praliciguat is being studied in a Phase 2 clinical trial with the identifier NCT07268638. This randomized, double-blind, placebo-controlled study is enrolling approximately 60 participants with Focal Segmental Glomerulosclerosis in the United States. The trial is currently recruiting adults aged 18 years and older.
No alternative names for Praliciguat have been reported. It is a distinct investigational compound being developed by Akebia Therapeutics for the treatment of Focal Segmental Glomerulosclerosis.